Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Infection in U.S. Adolescents
NCT07860112Phase 2Not yet recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label, single-arm trial of vonoprazan in Helicobacter pylori infection, sponsored by Boston Children's Hospital. Primary endpoint: Helicobacter Pylori Eradication Rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07860112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860112.